에 대한 최신 뉴스 Cigna (NYSE:CI) 주식

Cigna

Cigna Group

Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense, and it recently won a deal with top-tier insurer Centene. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, and the company operates mostly in the US with 18 million US medical members covered as of December 2023.

Government

Long Ideas

Regulations

Health Care

Trading Ideas

General

미국 연방거래위원회(FTC)가 유나이티드헬스 그룹(NYSE:UNH), CVS 헬스(NYSE:CVS) 및 시그나 그룹(NYSE:CI)의 처방약급여관리업체(PBM)들을 철저히 조사하고 있는 가운데, 투자자들은 어떤 의료 대기업이 이 위기를 가장 잘 이겨낼 수 있을지 궁금해하고 있다. 인슐린 가격을 부풀린 혐의로 이들 회사를 대상으로 한 이번 FTC의 소송은 의료 산업 전반에 큰 파급 효과를 미칠 수 있으며 이는 주식 변동성을 의미한다.

유나이티드헬스 vs CVS 헬스 vs 시그나: FTC 조사 및 규제 위기를 잘 이겨낼 의료 주식은?

The Cigna Group

AMUNDI INDIA B ETF

Citizens, Inc. Class A Common Stock ($1.00 Par)

Citizens Inc

CHINA MENGNIU DAIRY CO by China Mengniu Dairy Co., Ltd.

China Mengniu Dairy Co Ltd

CHINA MENGNIU DARY UN/ADR by China Mengniu Dairy Co., Ltd.

CHAMPION IRON LTD by Champion Iron Limited

Champion Iron Ltd

China Score Inc

BanColombia SA

COMML INTL BK S/ADR by Commercial International Bank Ltd.

Commercial International Bank - Egypt CIB

CIB MARINE BANCSHARES by CIB Marine Bancshares, Inc.

CIB Marine Bancshares Inc

COMMUTY INV BANCORP INC by Community Investors Bancorp, Inc.

Community Investors Bancorp Inc

First Trust NASDAQ Cybersecurity ETF

CIBL Inc

Capitol Investment Corp. VII

CHINA CONSTR BANK H by China Construction Bank Corp.

China Construction Bank Corp

CHINA CONSTR BK UNSP/ADR by China Construction Bank Corp.

SMS ALTERNATIVES INC by SMS Alternatives Inc.

SMS Alternatives Inc

COSCO SHIPPING HLDGS CO by COSCO SHIPPING Holdings Co Ltd.

COSCO SHIPPING Holdings Co Ltd

COSCO SHP HLDG UNSP/ADR by COSCO SHIPPING Holdings Co Ltd.

Capitol Investment Corp. VI

VictoryShares International High Div Volatility Wtd ETF

CLAL INSURANCE ENTERPRISE by CLAL INSURANCE ENTERPRISES HOLDINGS LTD.

CI EMERGING MARKET ALPHA USD UNT ETF

Ciena Corp

CHieru Co Ltd

CORPORACION INTERAMER B by Corporacion Intramericano Entretenimiento S.A.

Corporacion Interamericana de Entretenimiento SAB de CV

MFS Intermediate High Income Fund Common Stock

Mfs Intermediate High Income Fund

Cipher Mining Inc

Comp En De Mn Cemig ADS American Depositary Shares

Cia Energetica DE Minas Gerais - Cemig

Comp En De Mn Cemig ADS American Depositary Receipts

Colliers International Group Inc. - Subordinate Voting Shares

Colliers International Group Inc

Concorde International Group Ltd

CI GAMES SA by CI GAMES SA

CHINA MERCHANTS BK CO H by China Merchants Bank Co., Ltd.

China Merchants Bank Co Ltd

CHINA MRCHNTS BK UNSP/ADR by China Merchants Bank Co., Ltd.

CB INDUS PRODUCT HLDG BHD by CB Industrial Product Holding BHD

CB Industrial Product Holding Bhd

Blackrock Enhanced Cap&Inc Fund, Inc

CITIC SECURITIES CO LTD H by Citic Securities Co., Ltd.

CITIC Securities Co Ltd

CITIC SECURITIES UNSP/ADR by Citic Securities Co., Ltd.

TIANCI INTERNATIONAL INC by Tianci International Inc.

Tianci International Inc

Credit Suisse Asset Management Income Fund, Inc. Common Stock

Credit Suisse Asset Mgmt Income Fund Inc

VictoryShares International Volatility Wtd ETF

CHINA LIFE INS CO H SHS by China Life Insurance Company Limited

China Life Insurance Co Ltd

CAROLINA MILLS INC by Carolina Mills, Inc.

Carolina Mills Inc

Chimera Investment Corporation Common Stock

Chimera Investment Corp

CIMB GROUP HLDGS BHD ORD by CIMB Group Holdings BHD

CIMB Group Holdings Bhd

CIMC ENRIC HLDGS LTD ORD by CIMC Enric Holdings Ltd.

CIMC Enric Holdings Ltd

Chimera Investment Corporation 9.000% Senior Notes due 2029

Chimera Investment Corporation 9.250% Senior Notes due 2029

Pideka Group Inc

CIMAREX ENERGY 8 1/8 PFD by Cimarex Energy Co.

Chimera Investment Corporation 8.00% Series A Cumulative Redeemable Preferred Stock

Chimera Investment Corporation 8.00% Series B Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock

Chimera Investment Corporation 7.75% Series C Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock

Chimera Investment Corporation 8.00% Series D Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock

CHINA INDUSTRIAL GRP INC by China Industrial Group, Inc.

China Industrial Group

ISHRS DOW JONES IND AVRG USD ETF

Cincinnati Financial Corporation - Common Stock

Cincinnati Financial Corp

Cingulate Inc

COINSILIUM GROUP LTD ORD by Coinsilium Group Ltd.

Coinsilium Group Ltd

CHINA TAIPING INS HLD ORD by China Taiping Insurance Holdings Co Ltd.

China Taiping Insurance Holdings Co Ltd

CI&T Inc

CRUCIAL INNOVATIONS CORP by CRUCIAL INNOVATIONS CORP.

CI GLOBAL ALPHA INNOVATION USD ETF

City Office REIT Inc

CION Invt Corp

CENTRAL IRON ORE LIMITED by CENTRAL IRON ORE LIMITED

Central Iron Ore Ltd

CIELO SA S/ADR by Cielo SA

City Office REIT, Inc. 6.625% Series A Cumulative Redeemable Preferred Stock

CORRELATE ENERGY CORP by Correlate Energy Corp.

Correlate Energy Corp

JPMorgan Exchange-Traded Fund Trust Sustainable Consumption ETF

Cirus Foundation

CirTran Corp

Ciscom Corp

CHINA STEEL CP S/ADR 144A by China Steel Corp.

China Steel Corp

CISO Global Inc

C3is Inc

CHINA STEEL CORP S/GDR by China Steel Corp.

COSCO SHIPPING DEV CO LTD by Cosco Shipping Development Co Ltd.

Cosco Shipping Development Co Ltd

COSCO SHIP DEV UNSP/ADR by Cosco Shipping Development Co Ltd.

Cartica Acquisition Corp - Class A Ordinary Shares

Cartica Acquisition Corp

CRITICAL INFRASTUCTRE TCH by Critical Infrastructure Technologies Ltd.

Critical Infrastructure Technologies Ltd

AVALON CORRECTIONAL INC by Avalon Correctional Services, Inc.

Manchester City Fan Token

CITIZENS BANCSHARES CP SC by Citizens Bancshares Corp South Carolina

Citizens Bancshares Corp

Civilization

With the Federal Trade Commission (FTC) taking a scalpel to the pharmacy benefit managers (PBMs) of UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), CVS Health Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) and Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), investors are left wondering which health giant can best <a href="https://www.benzinga.com/general/health-care">weather the storm</a>.
The FTC's lawsuit, <a href="https://www.cnbc.com/2024/09/20/ftc-sues-drug-middlemen-for-allegedly-inflating-insulin-prices.html">targeting</a> these companies for allegedly inflating insulin prices, could have a major ripple effect across the healthcare industry—and that means stock volatility. 
So, which stock looks healthier?
<h1 class="wp-block-heading">UnitedHealth Group: Big &amp; Bold, But Under The Microscope</h1>
UnitedHealth Group&#8217;s OptumRx unit is at the heart of the FTC's lawsuit, and while UNH's sheer scale as a global leader in healthcare gives it plenty of muscle, it also makes it a big target. 
Analysts predict a modest <a href="https://www.benzinga.com/report/UNH">2.75% price movement</a> over the next 12 months, with a price target range of $591 to $680. UnitedHealth&#8217;s size could either serve as a shield or an anchor, depending on how the FTC&#8217;s hammer falls. 
For now, it's the heavyweight champ, but will its bulk keep it from dodging regulatory punches?
Read Also: <a href="https://www.benzinga.com/general/biotech/24/09/40820758/unitedhealth-follows-competitors-replaces-humira-with-lower-cost-biosimilars">UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars</a>
<h1 class="wp-block-heading">CVS Health: Retail Resilience Or Regulation Roadblock?</h1>
CVS Health, known for its 9,000-plus pharmacy locations and its PBM business Caremark, finds itself in the crosshairs, too.
Its integration with Aetna and recent Oak Street acquisition might help it spread risk, but the complexity of its operations also means more regulatory scrutiny. 
Analysts are predicting a price movement of around 6.36%, with a <a href="https://www.benzinga.com/report/CVS">12-month target of $63</a>. CVS is a diversified player, but being a jack-of-all-trades could make navigating the regulatory maze even trickier.
<h1 class="wp-block-heading">Cigna: Niche Focus, Bigger Moves?</h1>
Cigna, meanwhile, might just be the underdog to keep an eye on. Its PBM arm, Express Scripts, is a major player, but Cigna's more focused approach with self-funded plans and key government contracts could help it pivot more easily than its larger rivals. 
Analysts expect a more significant <a href="https://www.benzinga.com/report/CI">14.22% price movement</a> for Cigna, with a target range of $400 to $438. Cigna's smaller footprint in the broader health insurance landscape could allow it to sidestep the worst of the regulatory fallout and come out swinging.
<h1 class="wp-block-heading">Who's Got The Edge?</h1>
In this health stock showdown, the winner depends on how well these companies can adapt to the FTC's increasing scrutiny. 
UnitedHealth's size gives it strength but might make it a bigger target. CVS has a diversified portfolio but faces risks from its complexity. Cigna, while smaller, seems poised for the most price movement and could be the nimblest in dealing with the regulatory headwinds. 
Investors should keep a close eye on how this legal saga unfolds — there's more drama to come!
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40957261/wall-streets-most-accurate-analysts-weigh-in-on-3-health-care-stocks-with-over-3-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields</a></li>
</ul>
Photos: Shutterstock

UnitedHealth Vs. CVS Vs. Cigna: Which Health Stock Will Beat The FTC's Regulatory Heat?

On Friday, the Federal Trade Commission (FTC) filed a formal complaint against three major pharmacy benefit managers (PBMs)—CVS Health Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) Caremark, Cigna Corp&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) Express Scripts, and UnitedHealth Group Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) Optum—for allegedly engaging in unfair and anti-competitive practices that have inflated the list <a target="_blank" href="https://www.benzinga.com/government/24/07/39695378/ftc-investigation-uncovers-anti-competitive-practices-by-handful-of-pharmacy-benefit-managers-includ" rel="noreferrer noopener">price of insulin medications</a>.
The <a target="_blank" href="https://www.ftc.gov/news-events/news/press-releases/2024/09/ftc-sues-prescription-drug-middlemen-artificially-inflating-insulin-drug-prices" rel="noreferrer noopener">complaint</a> accuses the PBMs of creating a system that benefits them financially by prioritizing drug rebates, forcing patients to pay higher costs for life-saving insulin. These PBMs, referred to as the Big Three, administer around 80% of prescriptions in the U.S.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38564498/federal-trade-commission-targets-junk-patent-listings-for-diabetes-weight-loss-asthma-drugs-from-" rel="noreferrer noopener">Federal Trade Commission Targets &#8216;Junk Patent Listings&#8217; For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca</a>.
The FTC claims that the PBMs abused their market power to inflate insulin prices by promoting a rebate system with drug manufacturers.
This system led to the exclusion of lower-priced insulin from formularies, further driving up the cost for vulnerable patients.
The result is higher out-of-pocket expenses for those needing essential diabetes medication.
For example, the list price of Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Humalog rose dramatically from $21 in 1999 to over $274 in 2017.
Despite the availability of lower-priced alternatives, PBMs favored higher-priced drugs due to the lucrative rebates they provided.
The FTC is also examining the role of drug manufacturers, including Eli Lilly, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), and Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>), in driving up insulin prices, signaling potential further action against these companies.
The rebate-driven system excluded lower-priced insulins and allowed the Big Three PBMs to keep significant revenue in the form of rebates and fees, a strategy that hurt patients while benefiting the PBMs financially.
Vulnerable patients, such as those with high deductibles or coinsurance, bore the brunt of these inflated costs, paying more for their insulin than the overall net cost to insurers.
Price Action: At last check Friday, CVS stock was down 1.61% at $57.49, UNH stock was down 0.29% at $575.39, and CI stock was up 0.07% at $357.52.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40961594/mullen-automotive-gears-up-210m-ev-deal-in-dubai-delivers-first-units-to-volt-mobility" target="_blank" rel="noreferrer noopener">Mullen Automotive Gears Up $210M EV Deal In Dubai – Delivers First Units To Volt Mobility</a>.</li>
</ul>
Photo by towfiqu barbhuiya via unsplash

Large Cap

News

Legal

US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices

Cantor Fitzgerald analyst Sarah James reiterates Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Overweight and maintains $400 price target.

Price Target

Reiteration

Analyst Ratings

Cantor Fitzgerald Reiterates Overweight on Cigna, Maintains $400 Price Target

Jefferies analyst David Windley maintains Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Buy and raises the price target from $402 to $422.

Jefferies Maintains Buy on Cigna, Raises Price Target to $422

Cigna Subsidiary Express Scripts Files Lawsuit Against FTC, Demands Withdrawal Of PBM Report

Cigna's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) short percent of float has fallen 3.23% since its last report. The company recently reported that it has 3.34 million shares sold short, which is 1.2% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.22 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Cigna Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726166721_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cigna has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Cigna's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Cigna's peer group average for short interest as a percentage of float is 9.91%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(CI) - Analyzing Cigna's Short Interest

UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) reportedly announced on Tuesday that it will remove AbbVie Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) blockbuster drug Humira from some of its preferred reimbursement lists starting January 1, 2025. The company will recommend lower-cost biosimilar versions instead.
This move is part of a larger trend in the U.S. pharmaceutical market, as health plans seek to cut costs by promoting alternatives to high-priced drugs.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/24/07/39695378/ftc-investigation-uncovers-anti-competitive-practices-by-handful-of-pharmacy-benefit-managers-includ" rel="noreferrer noopener">FTC Investigation Uncovers Anti-Competitive Practices By Handful Of Pharmacy Benefit Managers, Including CVS Health, UnitedHealth</a>.
Reuters highlights that Amgen Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) Amjevita, managed by its pharmacy benefits unit, Optum Rx, is among the biosimilars covered under UnitedHealth&#8217;s lists for commercial health plans.
With this decision, Optum becomes the last of the three largest U.S. pharmacy benefit managers (PBMs) to exclude Humira.
Cigna Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) announced last month that it would remove Humira from some of its lists in 2025, following a similar decision by CVS Health Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) Caremark unit in April.
CVS&#8217;s action led to a swift shift, with more patients transitioning to Sandoz Group AG&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SDZNY#OTC">SDZNY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SDZXF#OTC">SDZXF</a>) biosimilar version of Humira in just three weeks than in the previous 15 months combined.
Cigna plans to cover biosimilars like Boehringer Ingelheim&#8217;s Cyltezo, Simlandi from Teva Pharmaceutical Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), and Alvotech&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) products, including an unbranded version of Sandoz&#8217;s Hyrimoz, as replacements for Humira.
UnitedHealth noted that patients would still have access to Humira until the FDA designates the preferred biosimilars as interchangeable with the original drug, per the report. The FDA is expected to make this designation in 2025.
Despite the growing competition, AbbVie has managed to retain a dominant share of the U.S. Humira market throughout 2023. This has been achieved through favorable negotiations with PBMs, even as biosimilar alternatives from companies like Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) entered the market.
As per a Reuters report, Humira has still managed to retain over 80% of its patients even after facing lower-priced rivals in the&nbsp;<a target="_blank" href="https://www.benzinga.com/news/large-cap/24/04/38468317/arthritis-patients-cignas-evernorth-to-offer-humira-biosimilar-at-no-out-of-pocket-cost" rel="noreferrer noopener">U.S. over the past year</a>.
Following their launch last year, pharmacy benefit managers largely influenced patient access, with minimal incentive for doctors to switch to <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39228916/abbvies-arthritis-drug-humira-retains-market-dominance-despite-biosimilar-competition-challenges-" rel="noreferrer noopener">these alternatives</a>.
In May, Cantor Fitzgerald said AbbVie had positioned itself to absorb Humira biosimilar erosion and achieve modest <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38899905/abbvie-is-successfully-positioned-to-absorb-humira-biosimilar-erosion-analyst" rel="noreferrer noopener">operational revenue growth</a>.
Price Action: UNH stock is down 2% at $587.07 at last check Wednesday.
Photo via Shutterstock
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40817991/gsk-halts-herpes-simplex-virus-vaccine-development-clears-path-for-other-contenders-like-moderna-" target="_blank" rel="noreferrer noopener">GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech</a>.</li>
</ul>

Biotech

Equities

Media

ABBV

ALVO

AMGN

SDZNY

SDZXF

TEVA

UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars

Shares of The Cigna Group (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ci#NYSE">CI</a>) have gained 25.6% in the past year compared with the industry&#39;s 18.2% growth. The Medical sector and the S&amp;P 500 composite index have rallied 9.3% and 21.2%, respectively, in the same time frame. CI has been well-poised for growth on the back of a sound membership base, solid Evernorth unit, acquisitions and expanding cash reserves.&nbsp;
Currently priced at $357.40, the stock is just 3.6% below its 52-week high of $370.64. This proximity underscores investor confidence and market optimism about Cigna&#39;s prospects.&nbsp;
The health insurer, presently carrying a Zacks Rank #3 (Hold), has an impressive record of beating estimates in each of the trailing four quarters, the average surprise being 3.83%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/a8/77228.jpg?v=810613562" />
Image Source: Zacks Investment Research
<h2>Robust Growth Prospects of CI Stock</h2>
The Zacks Consensus Estimate for Cigna&#39;s 2024 earnings is pegged at $28.48 per share, which indicates a 13.5% increase from the 2023 figure. The consensus mark for revenues is $239.1 billion, which implies 22.4% growth from the year-ago figure.&nbsp;
The Zacks Consensus Estimate for 2025 earnings is pegged at $31.80 per share, which implies an 11.7% improvement from the 2024 estimate. The consensus mark for revenues is $246.5 billion, implying a 3.1% rise from the 2024 estimate.
<h2>Cigna&#39;s Business Tailwinds</h2>
Cigna&#39;s performance is underscored its strong growth platforms, Evernorth and Cigna Healthcare. Evernorth is propelled by a range of specialty pharmacy services, significantly enhancing pharmacy revenues for the parent company. Pharmacy revenues saw a 31.8% year-over-year increase in the first half of 2024.&nbsp;
Conversely, Cigna Healthcare is strengthened by its sound customer base across the U.S. Healthcare business. This segment anticipates long-term average annual adjusted earnings growth in the band of 7-10%.&nbsp;
An expanding customer base leads to higher premiums, a critical revenue source for health insurers. As of June 30, 2024, Cigna served 19 million medical customers. The aging U.S. population is likely to drive continuous demand for its Medicare plans in the days ahead. In addition to premium growth, Cigna Healthcare benefits from ongoing product enhancements and new or extended partnerships with prominent healthcare systems.
Cigna strategically acquires companies to bolster its solutions and capabilities, broaden its geographical reach and reinforce its market presence. In alignment with its focus on high-growth platforms, it has divested its non-core health units. A robust cash balance and sufficient cash generation abilities allow the company to invest in business expansion and strategically allocate capital for share buybacks and dividends. Over the next five years, management anticipates cash flows of approximately $60 billion.
<h2>Stocks to Consider</h2>
Some better-ranked stocks in the Medical space are Universal Health Services, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uhs#NYSE">UHS</a>), The Ensign Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ensg#NASDAQ">ENSG</a>) and HCA Healthcare, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hca#NYSE">HCA</a>). Universal Health currently sports a Zacks Rank #1 (Strong Buy), and Ensign Group and HCA Healthcare carry a Zacks Rank #2 (Buy).
Universal Health&#39;s earnings surpassed the Zacks Consensus Estimate in each of the last four quarters, the average surprise being 14.58%. The consensus estimate for UHS&#39; 2024 earnings indicates a rise of 51% from the year-ago number. The consensus mark for revenues indicates growth of 9.8% from the year-ago figure.&nbsp;
The Zacks Consensus Estimate for UHS&#39; earnings has moved 15% north in the past 30 days. Shares of Universal Health have gained 73.7% in the past year.
Ensign Group&#39;s earnings outpaced the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 1.40%. The consensus estimate for ENSG&#39;s 2024 earnings indicates a rise of 14.1% from the year-ago number. The consensus mark for revenues implies an improvement of 13.1% from the year-ago figure.&nbsp;
The Zacks Consensus Estimate for ENSG&#39;s earnings has moved 0.7% north in the past 60 days. Shares of Ensign Group have risen 59.9% in the past year. &nbsp;
HCA Healthcare&#39;s earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and missed the mark once, the average surprise being 8.24%. The consensus estimate for HCA&#39;s 2024 earnings indicates an improvement of 18.2% from the year-ago figure. The consensus mark for revenues implies growth of 8.9% from the year-ago figure.&nbsp;
The Zacks Consensus Estimate for HCA&#39;s earnings has moved 1.2% north in the past seven days. Shares of HCA Healthcare have rallied 42% in the past year.
<a href="https://www.zacks.com/stock/news/2334211/cigna-stock-gains-26-in-a-year-what-lies-ahead-for-investors?cid=CS-BENZ-FT-analyst_blog|price_surge_/_plunge-2334211">To read this article on Zacks.com click here.</a>

Earnings

Earnings Beats

Mid Cap

Dividends

Buybacks

Management

Markets

ENSG

Cigna Stock Gains 26% in a Year: What Lies Ahead for Investors?

Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) has outperformed the market over the past 10 years by 3.83% on an annualized basis producing an average annual return of 14.39%. Currently, Cigna has a market capitalization of $99.95 billion. 
Buying $100 In CI: If an investor had bought $100 of CI stock 10 years ago, it would be worth $390.66 today based on a price of $357.53 for CI at the time of writing.
<h3>Cigna's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725982221_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Cigna Stock In The Last 10 Years

During the last three months, 8 analysts shared their evaluations of Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $404.62, a high estimate of $438.00, and a low estimate of $384.00. This upward trend is apparent, with the current average reflecting a 0.37% increase from the previous average price target of $403.14.
<img src="https://www.benzinga.com/files/images/story/2024/1725901279_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Cigna among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$384.00</td>
<td>$384.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$438.00</td>
<td>$435.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$410.00</td>
<td>$410.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$405.00</td>
<td>$393.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Overweight</td>
<td>$400.00</td>
<td>-</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Cigna. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Cigna compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Cigna's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Cigna's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Cigna analyst ratings.</a>
<h2>Discovering Cigna: A Closer Look</h2>
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense, and it recently won a deal with top-tier insurer Centene. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, and the company operates mostly in the US with 18 million US medical members covered as of December 2023.
<h3>Key Indicators: Cigna's Financial Health</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Cigna's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 24.4%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Cigna's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 2.56%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Cigna's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.75% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Cigna's ROA stands out, surpassing industry averages. With an impressive ROA of 1.0%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Cigna's debt-to-equity ratio is below the industry average. With a ratio of 0.77, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 8 Analysts Discuss Cigna Stock

RBC Capital analyst Ben Hendrix reiterates Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Outperform and maintains $384 price target.

RBC Capital Reiterates Outperform on Cigna, Maintains $384 Price Target

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$60.00</td>
<td>$32.4K</td>
<td>4.4K</td>
<td>1.0K</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/13/24</td>
<td>$141.00</td>
<td>$68.8K</td>
<td>144</td>
<td>406</td>
</tr>
<tr>
<td>CI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/06/24</td>
<td>$345.00</td>
<td>$106.1K</td>
<td>119</td>
<td>397</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$60.00</td>
<td>$81.1K</td>
<td>2.2K</td>
<td>226</td>
</tr>
<tr>
<td>TEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/06/24</td>
<td>$53.00</td>
<td>$29.0K</td>
<td>10</td>
<td>200</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$80.00</td>
<td>$25.3K</td>
<td>3.4K</td>
<td>183</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$175.00</td>
<td>$95.6K</td>
<td>3.2K</td>
<td>140</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$600.00</td>
<td>$41.6K</td>
<td>195</td>
<td>57</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$110.00</td>
<td>$30.5K</td>
<td>81</td>
<td>43</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$840.00</td>
<td>$48.6K</td>
<td>472</td>
<td>35</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we notice a call option sweep that happens to be bearish, expiring in 45 day(s) on October 18, 2024. This event was a transfer of 200 contract(s) at a $60.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $32.4K, with a price of $162.0 per contract. There were 4477 open contracts at this strike prior to today, and today 1063 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a call option sweep with bullish sentiment. It expires in 10 day(s) on September 13, 2024. Parties traded 398 contract(s) at a $141.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $68.8K, with a price of $172.0 per contract. There were 144 open contracts at this strike prior to today, and today 406 contract(s) were bought and sold. 
• Regarding CI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), we observe a call option sweep with bearish sentiment. It expires in 3 day(s) on September 6, 2024. Parties traded 50 contract(s) at a $345.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $106.1K, with a price of $2120.0 per contract. There were 119 open contracts at this strike prior to today, and today 397 contract(s) were bought and sold. 
• Regarding VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we observe a call option sweep with bullish sentiment. It expires in 17 day(s) on September 20, 2024. Parties traded 159 contract(s) at a $60.00 strike. This particular call needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $81.1K, with a price of $510.0 per contract. There were 2282 open contracts at this strike prior to today, and today 226 contract(s) were bought and sold. 
• Regarding TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we observe a put option sweep with bearish sentiment. It expires in 3 day(s) on September 6, 2024. Parties traded 100 contract(s) at a $53.00 strike. This particular put needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $29.0K, with a price of $290.0 per contract. There were 10 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• For MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we notice a call option trade that happens to be bearish, expiring in 45 day(s) on October 18, 2024. This event was a transfer of 65 contract(s) at a $80.00 strike. The total cost received by the writing party (or parties) was $25.3K, with a price of $390.0 per contract. There were 3412 open contracts at this strike prior to today, and today 183 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a call option trade that happens to be bullish, expiring in 17 day(s) on September 20, 2024. This event was a transfer of 40 contract(s) at a $175.00 strike. The total cost received by the writing party (or parties) was $95.6K, with a price of $2390.0 per contract. There were 3243 open contracts at this strike prior to today, and today 140 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a put option sweep that happens to be bullish, expiring in 73 day(s) on November 15, 2024. This event was a transfer of 16 contract(s) at a $600.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $41.6K, with a price of $2605.0 per contract. There were 195 open contracts at this strike prior to today, and today 57 contract(s) were bought and sold. 
• Regarding MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we observe a call option sweep with bullish sentiment. It expires in 199 day(s) on March 21, 2025. Parties traded 25 contract(s) at a $110.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $30.5K, with a price of $1220.0 per contract. There were 81 open contracts at this strike prior to today, and today 43 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option trade with bullish sentiment. It expires in 136 day(s) on January 17, 2025. Parties traded 3 contract(s) at a $840.00 strike. The total cost received by the writing party (or parties) was $48.6K, with a price of $16200.0 per contract. There were 472 open contracts at this strike prior to today, and today 35 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

MRNA

VKTX

10 Health Care Stocks With Whale Alerts In Today's Session

Guidance

Cigna Expects To Reaffirm Projected Full Year 2024 Consolidated Adjusted EPS From Operations Of At Least $28.40; Est $28.51

Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) has outperformed the market over the past 5 years by 4.19% on an annualized basis producing an average annual return of 18.06%. Currently, Cigna has a market capitalization of $98.96 billion. 
Buying $1000 In CI: If an investor had bought $1000 of CI stock 5 years ago, it would be worth $2,315.48 today based on a price of $353.99 for CI at the time of writing.
<h3>Cigna's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1724697012_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Cigna 5 Years Ago Would Be Worth Today

Rumors

Watching Cencora; Traders Circulate Unconfirmed Analyst Comments Suggesting The Co Has Lost Its Partnership With Cigna To Distribute Branded Humira; Cigna To Transition Distribution Through Its Specialty Distributor Curascript Starting January 2025

JP Morgan analyst Lisa Gill maintains Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Overweight and raises the price target from $435 to $438.

JP Morgan Maintains Overweight on Cigna, Raises Price Target to $438

Across the recent three months, 8 analysts have shared their insights on Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Cigna, revealing an average target of $404.75, a high estimate of $435.00, and a low estimate of $388.00. This current average has decreased by 0.27% from the previous average price target of $405.83. 
<img src="https://www.benzinga.com/files/images/story/2024/1724083213_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Cigna. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$410.00</td>
<td>$410.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$405.00</td>
<td>$393.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Overweight</td>
<td>$400.00</td>
<td>-</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$435.00</td>
<td>$432.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Announces</td>
<td>Outperform</td>
<td>$388.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Cigna. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Cigna compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Cigna's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Cigna's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Cigna analyst ratings.</a>
<h2>Unveiling the Story Behind Cigna</h2>
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense, and it recently won a deal with top-tier insurer Centene. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, and the company operates mostly in the US with 18 million US medical members covered as of December 2023.
<h3>Cigna's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Cigna's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 24.4%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Cigna's net margin is impressive, surpassing industry averages. With a net margin of 2.56%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Cigna's ROE stands out, surpassing industry averages. With an impressive ROE of 3.75%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Cigna's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.0% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.77, Cigna adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Ratings For Cigna

Fidelity Value Discovery Fund Q2 2024 Review

FOMC Preview: How Might Markets React After The Widely Expected Rate Cut

IHF: Healthcare Dashboard For September

Cigna's Express Scripts sues FTC over drug pricing report

Jefferies analyst David Windley maintained a Buy rating on Cigna (CI – Research Report) today and set a price target of $422.00. The company's shar...

Jefferies Sticks to Its Buy Rating for Cigna (CI)

Cigna's Express Scripts ($CI), one of the nation's major pharmacy-benefit managers PBMs), has sparked a significant legal showdown with the Federal...

Comments

Cigna

뉴스

에 대한 최신 뉴스 Cigna (NYSE:CI) 주식

토요일, 9월 21, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌